{"ticker": {"uuid": "8e7cf497-e8fb-443e-b08c-7ffcb3c2daf2", "symbol": "EBS", "name": "Emergent Biosolutions Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Emergent BioSolutions (EBS) AGM 2026 Summary", "summary": "The Emergent BioSolutions (EBS) 2026 AGM highlighted substantial progress on its multi-year turnaround plan, achieving improved financial results in 2025 including strong adjusted EBITDA, increased cash flow, and reduced debt. The agenda covered director elections, auditor ratifi", "url": "https://quartr.com/events/emergent-biosolutions-ebs-agm-2026_3PhrE4Ja", "source_name": "Quartr", "published_at": "2026-07-16T22:41:15", "published_display": "16 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) Proxy filing Summary", "summary": "Emergent BioSolutions (EBS) has released a proxy filing summary detailing their annual meeting scheduled for April 29, 2026. Shareholders of record as of March 6, 2026, are eligible to vote on various proposals, with a voting deadline of April 28, 2026. The company encourages rev", "url": "https://quartr.com/events/emergent-biosolutions-inc-ebs-proxy-filing_3PhrEVVe", "source_name": "Quartr", "published_at": "2026-07-16T16:41:15", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lobbying Update: $510,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed", "summary": "Emergent BioSolutions Inc. (EBS) recently disclosed $510,000 in lobbying expenditures for Q2 2026, targeting legislation related to pandemic preparedness, medical countermeasures, and opioid crisis interventions. Insiders at EBS have primarily sold stock in the past six months, w", "url": "https://www.quiverquant.com/news/Lobbying+Update%3A+%24510%2C000+of+EMERGENT+BIOSOLUTIONS+INC+lobbying+was+just+disclosed", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T20:08:00", "published_display": "14 Jul 2026 20:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBS5025998 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Emergent BioSolutions Inc. 3.875% 15-AUG-2028 bond, identified as EBS5025998. It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Furthermore, it offers a brief description of Emergent BioSolu", "url": "https://www.tradingview.com/symbols/FINRA-EBS5025998/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T18:37:18", "published_display": "14 Jul 2026 18:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Emergent BioSolutions Inc. \u2013 LS:A0LC2W", "summary": "This page provides information on the forward price-to-sales ratio for Emergent BioSolutions Inc. (LS:A0LC2W). It seems to be a financial data entry page, possibly from a financial charting and analysis platform, showing market data and company information, but the specific value", "url": "https://www.tradingview.com/symbols/LS-A0LC2W/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T09:10:16", "published_display": "14 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNaHJfVTgwSzlINVNwNEQzUFE4VDlHSUpLZkpFRVlRTkljbXFXcU1Yd0VYUXFDb2c3VWNTYU1salZkTDlqX21SVzVzcU04U0VobThicFQ3TDhuU3ZRSVBLbklmQVJsenFZRDZ6UGJ4WmlxckczUldQNDRZWXdHdVczdExIOEpfNnlReE5GcTkwY0hfZkJJd21qTWRQc2YxU1NmQ05YdjZDWWhkdDFSVHlsTWtrdWlqZ0xKdF9RR3lkOUFqZw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-09T04:39:24+00:00", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Paul Williams Sells 3,000 Shares of Emergent BioSo", "summary": "Paul Williams, Senior Vice President at Emergent BioSolutions Inc (EBS), sold 3,000 shares of the company on July 1, 2026. This transaction brings his total ownership to 159,098 shares. Over the last year, there have been 12 insider sells and no insider buys at EBS, and the stock", "url": "https://www.gurufocus.com/news/8943492/insider-sell-paul-williams-sells-3000-shares-of-emergent-biosolutions-inc-ebs", "source_name": "GuruFocus", "published_at": "2026-07-02T18:10:27", "published_display": "02 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions SVP Williams sells $25,200 in common stock", "summary": "Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., sold 3,000 shares of the company's common stock for $25,200 on July 1, 2026. The sale was executed at a weighted average price of $8.40 per share, pursuant to a pre-arranged trading p", "url": "https://www.investing.com/news/insider-trading-news/emergent-biosolutions-svp-williams-sells-25200-in-common-stock-93CH-4773731", "source_name": "Investing.com", "published_at": "2026-07-02T17:10:38", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan", "summary": "Emergent BioSolutions Inc.'s Senior Vice President, Paul Anthony Williams, sold 3,000 shares of common stock on July 1, 2026, at a weighted average price of $8.40 per share, totaling $25,200. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established", "url": "https://www.stocktitan.net/sec-filings/EBS/form-4-emergent-bio-solutions-inc-insider-trading-activity-30779cea70ec.html", "source_name": "Stock Titan", "published_at": "2026-07-02T17:10:38", "published_display": "02 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions SVP Williams sells $25,200 in common stock By Investing.com", "summary": "Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., sold 3,000 shares of company stock for $25,200 on July 1, 2026, at an average price of $8.40 per share. This sale was conducted under a pre-arranged trading plan. Following the transa", "url": "https://ca.investing.com/news/stock-market-news/emergent-biosolutions-svp-williams-sells-25200-in-common-stock-93CH-4718706", "source_name": "Investing.com Canada", "published_at": "2026-07-02T17:10:27", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Emergent Biosolutions Inc For: 2 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 by Emergent Biosolutions Inc. on July 2nd. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of the company's s", "url": "https://ca.investing.com/news/stock-market-news/form-4-emergent-biosolutions-inc-for-2-july-93CH-4718712", "source_name": "Investing.com Canada", "published_at": "2026-07-02T17:10:27", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144", "summary": "This article is a notice of a proposed sale of securities for Emergent BioSolutions pursuant to Rule 144. It indicates that the company will be filing the necessary documentation for this transaction.", "url": "https://www.moomoo.com/news/notice/307647748/emergent-biosolutions-144-notice-of-proposed-sale-of-securities-pursuant", "source_name": "Moomoo", "published_at": "2026-07-02T03:40:19", "published_display": "02 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Emergent BioSolutions Inc. SEC Filing", "summary": "Emergent BioSolutions Inc. (EBS) has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing indicates a proposed sale of 3,000 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $25,205.40. T", "url": "https://www.stocktitan.net/sec-filings/EBS/144-emergent-bio-solutions-inc-sec-filing-f7c1b48014fc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:30", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBS - Emergent Biosolutions Inc Options", "summary": "This article provides a detailed financial overview of Emergent Biosolutions Inc (EBS), including its stock performance, market valuation, income statement, balance sheet ratios, and analyst recommendations. It highlights key financial metrics such as market cap, sales, EPS, and ", "url": "https://finviz.com/stock?t=EBS&p=d&ty=oc&b=2&r=m3&e=2026-07-17&ov=list_date", "source_name": "Finviz", "published_at": "2026-06-30T12:10:38", "published_display": "30 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000", "summary": "Emergent BioSolutions has secured a contract modification worth approximately USD 52.7 million from the U.S. Department of Health and Human Services to supply its ACAM2000 vaccine. This vaccine, which protects against smallpox and mpox, along with ancillaries and diluent replacem", "url": "https://www.marketscreener.com/news/emergent-biosolutions-secures-contract-modification-valued-at-approximately-usd-52-7-million-from-th-ce7f5fdfdb88ff2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:41:02", "published_display": "29 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (NYSE: EBS) lands $52.7M U.S. ACAM2000 contract", "summary": "Emergent BioSolutions secured a $52.7 million contract modification from the U.S. Administration for Strategic Preparedness and Response to supply its ACAM2000 smallpox and mpox vaccine, related ancillaries, and diluent replacement lots. This modification, designated Option Year ", "url": "https://www.stocktitan.net/sec-filings/EBS/8-k-emergent-bio-solutions-inc-reports-material-event-f5b17ad06d81.html", "source_name": "Stock Titan", "published_at": "2026-06-29T15:41:01", "published_display": "29 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent Gets $52.7 Million Contract Modification From US Government", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/emergent-gets-52-7-million-143134722.html", "source_name": "MT Newswires", "published_at": "2026-06-29T14:31:34+00:00", "published_display": "29 Jun 2026 14:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/emergent-biosolutions-secures-contract-modification-131300819.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T13:13:00+00:00", "published_display": "29 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. government adds $52.7M ACAM2000 order for smallpox preparedness", "summary": "Emergent BioSolutions (NYSE: EBS) secured a $52.7 million contract modification from the U.S. government for its ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine. This order, part of an existing 10-year agreement, aims to bolster U.S. preparedness against smallpox a", "url": "https://www.stocktitan.net/news/EBS/emergent-bio-solutions-secures-contract-modification-valued-at-6qk4rt21pk1x.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:41:02", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions | 8-K: Current report", "summary": "This article is a current report (8-K filing) from Emergent BioSolutions. It indicates that further details about the report can be found by accessing the document linked within the content.", "url": "https://www.moomoo.com/news/notice/307622408/emergent-biosolutions-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-06-26T22:41:02", "published_display": "26 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Emergent BioSolutions Inc. \u2013 NYSE:EBS", "summary": "This article provides financial information for Emergent BioSolutions Inc. (NYSE: EBS), specifically focusing on its forward price to sales metric. It appears to be a data point or a financial snapshot from a platform like TradingView, with no further analytical content.", "url": "https://www.tradingview.com/symbols/NYSE-EBS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:00", "published_display": "26 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc. Actuals & Estimates (NYSE:EBS)", "summary": "This article provides an overview of Emergent BioSolutions Inc. (NYSE: EBS), detailing its financial actuals and estimates, stock performance, and analyst forecasts. It covers key financial metrics like revenue, net income, and EBITDA, along with stock volatility, market capitali", "url": "https://www.tradingview.com/symbols/NYSE-EBS/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:09:31", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Emergent BioSolutions Inc. \u2013 NYSE:EBS", "summary": "This article displays information regarding the Price to Earnings Forward for Emergent BioSolutions Inc. (NYSE: EBS). It is presented as a financial data point without further analysis or contextual details. The page seems to be a static data point from a financial platform like ", "url": "https://www.tradingview.com/symbols/NYSE-EBS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:29", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Emergent BioSolutions Inc. \u2013 BOATS:EBS", "summary": "This article provides the title and stock symbol for Emergent BioSolutions Inc. (EBS) within the context of its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data page on TradingView, focusing on the company's financial metrics. T", "url": "https://www.tradingview.com/symbols/BOATS-EBS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:41:29", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis", "summary": "Emergent BioSolutions Inc (EBS) currently has a valuation score of 9.26, ranking 38th out of 157 in the Pharmaceuticals industry. The article highlights its current P/E ratio of -59.94, which is significantly below its recent high but above its recent low. Key valuation metrics l", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:23", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its support and resistance levels, indicator analysis, and moving averages. The stock is currently trading between a resistance of $9.17 and a support of $7.33, making it suitable for range-b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:23", "published_display": "18 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Emergent BioSolutions Inc (EBS), categorized by business segments and regional contributions. Data for various fiscal years and quarters is presented, highlighting key revenue streams like Commercial Product sales, MCM Produc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:45", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Emergent BioSolutions Inc (EBS) stock, focusing on its dividend history and stock splits. It notes that the company has distributed no dividends over the past five years and has no recorded stock split data. The page also presents current stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:45", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Stock (US29089Q1058): Earnings Picture And Balance Sheet Under The Microscope", "summary": "Emergent BioSolutions is currently navigating a challenging period characterized by weak earnings, high leverage, and a major restructuring effort following a difficult 2024. The company is actively shifting its focus from lower-margin contract manufacturing towards core medical ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/emergent-biosolutions-stock-us29089q1058-earnings-picture-and-balance/69554946", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T16:18:33", "published_display": "16 Jun 2026 16:18", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes", "summary": "Emergent BioSolutions Inc.'s SVP of Products Business, Paul Anthony Williams, had 694 shares of common stock withheld at $8.00 per share to cover tax obligations upon the vesting of restricted stock units. This transaction was a routine tax-related disposition, not an open-market", "url": "https://www.stocktitan.net/sec-filings/EBS/form-4-emergent-bio-solutions-inc-insider-trading-activity-50a33d28ae89.html", "source_name": "Stock Titan", "published_at": "2026-06-11T15:39:37", "published_display": "11 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come (NYSE:EBS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPc2tOdGRQUzBBYVBsNmtUVXRNLS12U21mOWU3QVJKc3dqRFNlVE1sQ0dGUW05SnFVcF9HZmZwczc2al85dFRUNmZnVjdqeW9LUUtmOXVvRl8xS3p4My1xTVpHV0UxamxvYXk1RU9YcnluLW56bzdVX2VXM1JNdjFXOFQyd09zRUZhTVNfVXFDWE9fYk5GNlBVQVF4S3BlaW1zWG50V3ZsYUttUVdLbXU1cjB6emFzaUx4allKSw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Supports Victoria\u2019s Voice Foundation\u2019s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-supports-victoria-voice-120200035.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:02:00+00:00", "published_display": "04 Jun 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-wins-64-5-213153525.html", "source_name": "MT Newswires", "published_at": "2026-05-28T21:31:53+00:00", "published_display": "28 May 2026 21:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-receives-64-5-200100423.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:01:00+00:00", "published_display": "28 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. health agency awards $64.5M botulism antitoxin deal to Emergent", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdV9UR29jb3I5ZlNtQjR6NEtNcm9meFZmZG1uY1NycWtuWnFIN01kak5Od0hUUHJIV056a1RLNC1sUVpLVXFkanJBYWdSb3pINXY0cTVoMDlleFM4aEx6c256RG5nZE9kSFVZcm4wQlFvVHVYcnlSeDkwRE1HZG9FTGNybEZGcmRTVjZiWEVtb0VMcjRmSVV0ejNFajZVdzJXbDVSUjhUMkVfZkVfQnhwU0U1a2tjM2ZfY281NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-participate-upcoming-investor-113000886.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T11:30:00+00:00", "published_display": "20 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNZEMyREN1eE03c3BtUXNXZWZyVFZHSEpnRDJFQkMyR1NMOU4yOVBocWFLLU0zc0ZlUHBtcFFSODR4TDJISEFNODZWNUowYUg5c2dqWTlOa1ZDS1hqVlJDY19DVGxIVnB0eGxSX21Qc1JwdG5YNGVjRUhaNTZUVmFXenAwZjd3MWl3UUMxRWpDYUQ3Y0d6aFFOS2tUVE5jTGRuQUI4V1I5UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for Smallpox, Mpox Vaccine", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-receives-saudi-food-132150298.html", "source_name": "MT Newswires", "published_at": "2026-05-18T13:21:50+00:00", "published_display": "18 May 2026 13:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000\u00ae [Smallpox and Mpox (Vaccinia) Vaccine, Live]", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-receives-saudi-food-125900765.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:59:00+00:00", "published_display": "18 May 2026 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved", "summary": "", "url": "https://finance.yahoo.com/m/108ef779-f2c4-3404-a610-f1c567ef7b25/emergent-biosolutions-shares.html", "source_name": "MarketBeat", "published_at": "2026-05-02T14:29:55+00:00", "published_display": "02 May 2026 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) Stock Rises on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNajZWQklPYzc3NzlHRjh6Q2V2d0Z4SUcyU0lDdEZ1QXAzSDdibXUzR1R0SXIyVm5pcnk4RUdZZmw2V0RhaHpiLTJfb21VcTYxRzVqNXZjWHFQNUJJbEpMYVlyaU9XdFpPWW1jZV9ZN1VhSG9UX0RyVDRQX2xFU3JDTXZyTTVObnEzbmNVWWV3RE9QNS1Cc3d3Umo0bG0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Emerging Narrative On Emergent BioSolutions (EBS) Is Shifting After The Earnings Miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOUFhJM2c2M05TV25fVU5oZmtUeEQ5VlNWWlZsa2xaUlVLd2hfcHUyOW43UGlUbDBDOHh4R3pubnBuRVdveUJVRWtpUHhwSTY0U0I5ajYtTkFndWxyOERYQ3BaS0p5VENicFNENG9QS2k3alRHTVZCaFFabGY2ZjJOeVFwUlJMbXZSU1lsaWQtS1RyOGVGQmM3X0E5QzdPZjZBTXZ1cUZoZmdIbXJuQUE?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRU9lQ3QyQlVqd2ZNZG9lNXE5TklOZDdndnh3V0pfWXR1Y0ZUUlpGZDZYN1Rsems0RWVfSHNNMlo1SndDVTZCNjlid1FrTmdVYnc3ckMzNDdybEExTzRpbHM4bWdtd3J0UTlpdUozUVdFbUt4cjlNNU9Jd2J6TVR5T281RXk4MGh5WkRvS2xEZmxaa1A4Vkw4b0dFYUhsLW5lLVE?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOLUZWZi1NOVFOYXoyeXl1bjdxbVBYZWlVdzJTUHhhakNVRnBtLXVCSlBzdVRqd3ZvYmplTW83ZkROLV9MTVdyaGVHczFqdHNxWGxnbHR4ZWZablhkdnRncUxGV1NIXzFFeWktd2tFWjJISDV5LVVaU0pha2V0SVNENlVMYi1NMDFZSnhPOEdQbWxsbXpKUlRF?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (NYSE: EBS) swings from 2024 loss to 2025 profit", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPYzV4TERMcmc3dTFvV0pvVklMR2JObk1xSnJXOVh1M1JqY2hpbTI3Q0lvc2tXR3l1SFhlV3lydk1fa0lfMjNNRHpYSUJwX01rZUxvNkUxeGR3VDFEVVNlYzVUNzVTVl9UaW9rdjlNakF4S3JRV1VfaFhtc1RST01UUC1tRmpUYTFJUDV3N1BRN25ENFdxcGdjMW5hZWlnTnI0UDdMWDR4S2xDbTZPY0VGeHF6TDU?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Stock Price Today: $7.50", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE8zdXEtQkVuSWlxajJHLXp1TXRIcllfUTMtRVo3Ul83Ri1IYmhJYm1kVWw5b0ZmakpKSC1xeURoTTdNbTZaOGlCSmJwTFNoc0pqbHBwUGdn?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T06:35:18+00:00", "published_display": "02 Feb 2026 06:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQT3NjSEVzWDFWUGM5YnBpRkcyenJUUzgyd1c5QkxyalRpX3NMVDZEN3VCdTdhUUNsYWwyRzA1Y1R5SHFOY3drVnRBQzhYdk90WjdLNFh0X3VrMTdqbmJINzlhM1JUdTlrOWhodnNTbFRsSWtEWC12UTV0TGxyd0JHY0Vjcl9CNGhPR0ZQZ3RmRkdmNjVtMFlDQjY2RHk0TUphQW5UYVIxZk9lQUZYbWUtV3M4MldpelJFTlYtUEpFdzd6cDd4REp0RUJDYkd1UG0xLWs3aThUMFVTZ3hXTWs2dWFTWG5lR1U?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-15T22:09:08+00:00", "published_display": "15 Jan 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-20T08:00:00+00:00", "published_display": "20 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS): Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-02T07:00:00+00:00", "published_display": "02 Nov 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is \u2018Significantly Undervalued\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOWThJUHFGUjM4WFNPS0NrVjJKOFk5MmRTTnV6UHJvSVRrTnRYS0hOYk5keFNfbUplazIxWUU0bkNSbnRXU294Vmx0X2tHRHNvd1oxNzE5aXlzdHpQZW5tbU5xbHZVNmV0Z1o4blJFeG9fakdPOHFLd3ZkeXprZ1NMOF9CZ1Z2dVJDYlBuWFlqWjlPYV9FeWp4dFZTUXJWNVV4S3pUclZ6MFN4OUpjUmVHdU1qeEl3MVY1N3ltMEhhbkdOMmhITDk1WllOQmhlRVJOR1NIaHpEdm1BS0N2QTF4eUladw?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-19T16:16:57+00:00", "published_display": "19 Sep 2025 16:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sellers Might Regret Selling Emergent BioSolutions Shares at a Lower Price Than Current Market Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Emergent BioSolutions (EBS) AGM 2026 Summary", "summary": "The Emergent BioSolutions (EBS) 2026 AGM highlighted substantial progress on its multi-year turnaround plan, achieving improved financial results in 2025 including strong adjusted EBITDA, increased cash flow, and reduced debt. The agenda covered director elections, auditor ratifi", "url": "https://quartr.com/events/emergent-biosolutions-ebs-agm-2026_3PhrE4Ja", "source_name": "Quartr", "published_at": "2026-07-16T22:41:15", "published_display": "16 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) Proxy filing Summary", "summary": "Emergent BioSolutions (EBS) has released a proxy filing summary detailing their annual meeting scheduled for April 29, 2026. Shareholders of record as of March 6, 2026, are eligible to vote on various proposals, with a voting deadline of April 28, 2026. The company encourages rev", "url": "https://quartr.com/events/emergent-biosolutions-inc-ebs-proxy-filing_3PhrEVVe", "source_name": "Quartr", "published_at": "2026-07-16T16:41:15", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lobbying Update: $510,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed", "summary": "Emergent BioSolutions Inc. (EBS) recently disclosed $510,000 in lobbying expenditures for Q2 2026, targeting legislation related to pandemic preparedness, medical countermeasures, and opioid crisis interventions. Insiders at EBS have primarily sold stock in the past six months, w", "url": "https://www.quiverquant.com/news/Lobbying+Update%3A+%24510%2C000+of+EMERGENT+BIOSOLUTIONS+INC+lobbying+was+just+disclosed", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T20:08:00", "published_display": "14 Jul 2026 20:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBS5025998 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Emergent BioSolutions Inc. 3.875% 15-AUG-2028 bond, identified as EBS5025998. It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Furthermore, it offers a brief description of Emergent BioSolu", "url": "https://www.tradingview.com/symbols/FINRA-EBS5025998/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T18:37:18", "published_display": "14 Jul 2026 18:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Emergent BioSolutions Inc. \u2013 LS:A0LC2W", "summary": "This page provides information on the forward price-to-sales ratio for Emergent BioSolutions Inc. (LS:A0LC2W). It seems to be a financial data entry page, possibly from a financial charting and analysis platform, showing market data and company information, but the specific value", "url": "https://www.tradingview.com/symbols/LS-A0LC2W/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T09:10:16", "published_display": "14 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNaHJfVTgwSzlINVNwNEQzUFE4VDlHSUpLZkpFRVlRTkljbXFXcU1Yd0VYUXFDb2c3VWNTYU1salZkTDlqX21SVzVzcU04U0VobThicFQ3TDhuU3ZRSVBLbklmQVJsenFZRDZ6UGJ4WmlxckczUldQNDRZWXdHdVczdExIOEpfNnlReE5GcTkwY0hfZkJJd21qTWRQc2YxU1NmQ05YdjZDWWhkdDFSVHlsTWtrdWlqZ0xKdF9RR3lkOUFqZw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-09T04:39:24+00:00", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Paul Williams Sells 3,000 Shares of Emergent BioSo", "summary": "Paul Williams, Senior Vice President at Emergent BioSolutions Inc (EBS), sold 3,000 shares of the company on July 1, 2026. This transaction brings his total ownership to 159,098 shares. Over the last year, there have been 12 insider sells and no insider buys at EBS, and the stock", "url": "https://www.gurufocus.com/news/8943492/insider-sell-paul-williams-sells-3000-shares-of-emergent-biosolutions-inc-ebs", "source_name": "GuruFocus", "published_at": "2026-07-02T18:10:27", "published_display": "02 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions SVP Williams sells $25,200 in common stock", "summary": "Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., sold 3,000 shares of the company's common stock for $25,200 on July 1, 2026. The sale was executed at a weighted average price of $8.40 per share, pursuant to a pre-arranged trading p", "url": "https://www.investing.com/news/insider-trading-news/emergent-biosolutions-svp-williams-sells-25200-in-common-stock-93CH-4773731", "source_name": "Investing.com", "published_at": "2026-07-02T17:10:38", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan", "summary": "Emergent BioSolutions Inc.'s Senior Vice President, Paul Anthony Williams, sold 3,000 shares of common stock on July 1, 2026, at a weighted average price of $8.40 per share, totaling $25,200. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established", "url": "https://www.stocktitan.net/sec-filings/EBS/form-4-emergent-bio-solutions-inc-insider-trading-activity-30779cea70ec.html", "source_name": "Stock Titan", "published_at": "2026-07-02T17:10:38", "published_display": "02 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions SVP Williams sells $25,200 in common stock By Investing.com", "summary": "Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., sold 3,000 shares of company stock for $25,200 on July 1, 2026, at an average price of $8.40 per share. This sale was conducted under a pre-arranged trading plan. Following the transa", "url": "https://ca.investing.com/news/stock-market-news/emergent-biosolutions-svp-williams-sells-25200-in-common-stock-93CH-4718706", "source_name": "Investing.com Canada", "published_at": "2026-07-02T17:10:27", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Emergent Biosolutions Inc For: 2 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 by Emergent Biosolutions Inc. on July 2nd. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of the company's s", "url": "https://ca.investing.com/news/stock-market-news/form-4-emergent-biosolutions-inc-for-2-july-93CH-4718712", "source_name": "Investing.com Canada", "published_at": "2026-07-02T17:10:27", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144", "summary": "This article is a notice of a proposed sale of securities for Emergent BioSolutions pursuant to Rule 144. It indicates that the company will be filing the necessary documentation for this transaction.", "url": "https://www.moomoo.com/news/notice/307647748/emergent-biosolutions-144-notice-of-proposed-sale-of-securities-pursuant", "source_name": "Moomoo", "published_at": "2026-07-02T03:40:19", "published_display": "02 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Emergent BioSolutions Inc. SEC Filing", "summary": "Emergent BioSolutions Inc. (EBS) has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing indicates a proposed sale of 3,000 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $25,205.40. T", "url": "https://www.stocktitan.net/sec-filings/EBS/144-emergent-bio-solutions-inc-sec-filing-f7c1b48014fc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:30", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBS - Emergent Biosolutions Inc Options", "summary": "This article provides a detailed financial overview of Emergent Biosolutions Inc (EBS), including its stock performance, market valuation, income statement, balance sheet ratios, and analyst recommendations. It highlights key financial metrics such as market cap, sales, EPS, and ", "url": "https://finviz.com/stock?t=EBS&p=d&ty=oc&b=2&r=m3&e=2026-07-17&ov=list_date", "source_name": "Finviz", "published_at": "2026-06-30T12:10:38", "published_display": "30 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000", "summary": "Emergent BioSolutions has secured a contract modification worth approximately USD 52.7 million from the U.S. Department of Health and Human Services to supply its ACAM2000 vaccine. This vaccine, which protects against smallpox and mpox, along with ancillaries and diluent replacem", "url": "https://www.marketscreener.com/news/emergent-biosolutions-secures-contract-modification-valued-at-approximately-usd-52-7-million-from-th-ce7f5fdfdb88ff2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:41:02", "published_display": "29 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (NYSE: EBS) lands $52.7M U.S. ACAM2000 contract", "summary": "Emergent BioSolutions secured a $52.7 million contract modification from the U.S. Administration for Strategic Preparedness and Response to supply its ACAM2000 smallpox and mpox vaccine, related ancillaries, and diluent replacement lots. This modification, designated Option Year ", "url": "https://www.stocktitan.net/sec-filings/EBS/8-k-emergent-bio-solutions-inc-reports-material-event-f5b17ad06d81.html", "source_name": "Stock Titan", "published_at": "2026-06-29T15:41:01", "published_display": "29 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent Gets $52.7 Million Contract Modification From US Government", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/emergent-gets-52-7-million-143134722.html", "source_name": "MT Newswires", "published_at": "2026-06-29T14:31:34+00:00", "published_display": "29 Jun 2026 14:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/emergent-biosolutions-secures-contract-modification-131300819.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T13:13:00+00:00", "published_display": "29 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. government adds $52.7M ACAM2000 order for smallpox preparedness", "summary": "Emergent BioSolutions (NYSE: EBS) secured a $52.7 million contract modification from the U.S. government for its ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine. This order, part of an existing 10-year agreement, aims to bolster U.S. preparedness against smallpox a", "url": "https://www.stocktitan.net/news/EBS/emergent-bio-solutions-secures-contract-modification-valued-at-6qk4rt21pk1x.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:41:02", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions | 8-K: Current report", "summary": "This article is a current report (8-K filing) from Emergent BioSolutions. It indicates that further details about the report can be found by accessing the document linked within the content.", "url": "https://www.moomoo.com/news/notice/307622408/emergent-biosolutions-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-06-26T22:41:02", "published_display": "26 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Emergent BioSolutions Inc. \u2013 NYSE:EBS", "summary": "This article provides financial information for Emergent BioSolutions Inc. (NYSE: EBS), specifically focusing on its forward price to sales metric. It appears to be a data point or a financial snapshot from a platform like TradingView, with no further analytical content.", "url": "https://www.tradingview.com/symbols/NYSE-EBS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:00", "published_display": "26 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc. Actuals & Estimates (NYSE:EBS)", "summary": "This article provides an overview of Emergent BioSolutions Inc. (NYSE: EBS), detailing its financial actuals and estimates, stock performance, and analyst forecasts. It covers key financial metrics like revenue, net income, and EBITDA, along with stock volatility, market capitali", "url": "https://www.tradingview.com/symbols/NYSE-EBS/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:09:31", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Emergent BioSolutions Inc. \u2013 NYSE:EBS", "summary": "This article displays information regarding the Price to Earnings Forward for Emergent BioSolutions Inc. (NYSE: EBS). It is presented as a financial data point without further analysis or contextual details. The page seems to be a static data point from a financial platform like ", "url": "https://www.tradingview.com/symbols/NYSE-EBS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:29", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Emergent BioSolutions Inc. \u2013 BOATS:EBS", "summary": "This article provides the title and stock symbol for Emergent BioSolutions Inc. (EBS) within the context of its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data page on TradingView, focusing on the company's financial metrics. T", "url": "https://www.tradingview.com/symbols/BOATS-EBS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:41:29", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis", "summary": "Emergent BioSolutions Inc (EBS) currently has a valuation score of 9.26, ranking 38th out of 157 in the Pharmaceuticals industry. The article highlights its current P/E ratio of -59.94, which is significantly below its recent high but above its recent low. Key valuation metrics l", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:23", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its support and resistance levels, indicator analysis, and moving averages. The stock is currently trading between a resistance of $9.17 and a support of $7.33, making it suitable for range-b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:23", "published_display": "18 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Emergent BioSolutions Inc (EBS), categorized by business segments and regional contributions. Data for various fiscal years and quarters is presented, highlighting key revenue streams like Commercial Product sales, MCM Produc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:45", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Emergent BioSolutions Inc (EBS) stock, focusing on its dividend history and stock splits. It notes that the company has distributed no dividends over the past five years and has no recorded stock split data. The page also presents current stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ebs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:45", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Stock (US29089Q1058): Earnings Picture And Balance Sheet Under The Microscope", "summary": "Emergent BioSolutions is currently navigating a challenging period characterized by weak earnings, high leverage, and a major restructuring effort following a difficult 2024. The company is actively shifting its focus from lower-margin contract manufacturing towards core medical ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/emergent-biosolutions-stock-us29089q1058-earnings-picture-and-balance/69554946", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T16:18:33", "published_display": "16 Jun 2026 16:18", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes", "summary": "Emergent BioSolutions Inc.'s SVP of Products Business, Paul Anthony Williams, had 694 shares of common stock withheld at $8.00 per share to cover tax obligations upon the vesting of restricted stock units. This transaction was a routine tax-related disposition, not an open-market", "url": "https://www.stocktitan.net/sec-filings/EBS/form-4-emergent-bio-solutions-inc-insider-trading-activity-50a33d28ae89.html", "source_name": "Stock Titan", "published_at": "2026-06-11T15:39:37", "published_display": "11 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come (NYSE:EBS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPc2tOdGRQUzBBYVBsNmtUVXRNLS12U21mOWU3QVJKc3dqRFNlVE1sQ0dGUW05SnFVcF9HZmZwczc2al85dFRUNmZnVjdqeW9LUUtmOXVvRl8xS3p4My1xTVpHV0UxamxvYXk1RU9YcnluLW56bzdVX2VXM1JNdjFXOFQyd09zRUZhTVNfVXFDWE9fYk5GNlBVQVF4S3BlaW1zWG50V3ZsYUttUVdLbXU1cjB6emFzaUx4allKSw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Supports Victoria\u2019s Voice Foundation\u2019s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-supports-victoria-voice-120200035.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:02:00+00:00", "published_display": "04 Jun 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-wins-64-5-213153525.html", "source_name": "MT Newswires", "published_at": "2026-05-28T21:31:53+00:00", "published_display": "28 May 2026 21:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-receives-64-5-200100423.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:01:00+00:00", "published_display": "28 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. health agency awards $64.5M botulism antitoxin deal to Emergent", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdV9UR29jb3I5ZlNtQjR6NEtNcm9meFZmZG1uY1NycWtuWnFIN01kak5Od0hUUHJIV056a1RLNC1sUVpLVXFkanJBYWdSb3pINXY0cTVoMDlleFM4aEx6c256RG5nZE9kSFVZcm4wQlFvVHVYcnlSeDkwRE1HZG9FTGNybEZGcmRTVjZiWEVtb0VMcjRmSVV0ejNFajZVdzJXbDVSUjhUMkVfZkVfQnhwU0U1a2tjM2ZfY281NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-participate-upcoming-investor-113000886.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T11:30:00+00:00", "published_display": "20 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNZEMyREN1eE03c3BtUXNXZWZyVFZHSEpnRDJFQkMyR1NMOU4yOVBocWFLLU0zc0ZlUHBtcFFSODR4TDJISEFNODZWNUowYUg5c2dqWTlOa1ZDS1hqVlJDY19DVGxIVnB0eGxSX21Qc1JwdG5YNGVjRUhaNTZUVmFXenAwZjd3MWl3UUMxRWpDYUQ3Y0d6aFFOS2tUVE5jTGRuQUI4V1I5UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for Smallpox, Mpox Vaccine", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-receives-saudi-food-132150298.html", "source_name": "MT Newswires", "published_at": "2026-05-18T13:21:50+00:00", "published_display": "18 May 2026 13:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000\u00ae [Smallpox and Mpox (Vaccinia) Vaccine, Live]", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/emergent-biosolutions-receives-saudi-food-125900765.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:59:00+00:00", "published_display": "18 May 2026 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved", "summary": "", "url": "https://finance.yahoo.com/m/108ef779-f2c4-3404-a610-f1c567ef7b25/emergent-biosolutions-shares.html", "source_name": "MarketBeat", "published_at": "2026-05-02T14:29:55+00:00", "published_display": "02 May 2026 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS) Stock Rises on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNajZWQklPYzc3NzlHRjh6Q2V2d0Z4SUcyU0lDdEZ1QXAzSDdibXUzR1R0SXIyVm5pcnk4RUdZZmw2V0RhaHpiLTJfb21VcTYxRzVqNXZjWHFQNUJJbEpMYVlyaU9XdFpPWW1jZV9ZN1VhSG9UX0RyVDRQX2xFU3JDTXZyTTVObnEzbmNVWWV3RE9QNS1Cc3d3Umo0bG0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Emerging Narrative On Emergent BioSolutions (EBS) Is Shifting After The Earnings Miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOUFhJM2c2M05TV25fVU5oZmtUeEQ5VlNWWlZsa2xaUlVLd2hfcHUyOW43UGlUbDBDOHh4R3pubnBuRVdveUJVRWtpUHhwSTY0U0I5ajYtTkFndWxyOERYQ3BaS0p5VENicFNENG9QS2k3alRHTVZCaFFabGY2ZjJOeVFwUlJMbXZSU1lsaWQtS1RyOGVGQmM3X0E5QzdPZjZBTXZ1cUZoZmdIbXJuQUE?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRU9lQ3QyQlVqd2ZNZG9lNXE5TklOZDdndnh3V0pfWXR1Y0ZUUlpGZDZYN1Rsems0RWVfSHNNMlo1SndDVTZCNjlid1FrTmdVYnc3ckMzNDdybEExTzRpbHM4bWdtd3J0UTlpdUozUVdFbUt4cjlNNU9Jd2J6TVR5T281RXk4MGh5WkRvS2xEZmxaa1A4Vkw4b0dFYUhsLW5lLVE?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOLUZWZi1NOVFOYXoyeXl1bjdxbVBYZWlVdzJTUHhhakNVRnBtLXVCSlBzdVRqd3ZvYmplTW83ZkROLV9MTVdyaGVHczFqdHNxWGxnbHR4ZWZablhkdnRncUxGV1NIXzFFeWktd2tFWjJISDV5LVVaU0pha2V0SVNENlVMYi1NMDFZSnhPOEdQbWxsbXpKUlRF?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (NYSE: EBS) swings from 2024 loss to 2025 profit", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPYzV4TERMcmc3dTFvV0pvVklMR2JObk1xSnJXOVh1M1JqY2hpbTI3Q0lvc2tXR3l1SFhlV3lydk1fa0lfMjNNRHpYSUJwX01rZUxvNkUxeGR3VDFEVVNlYzVUNzVTVl9UaW9rdjlNakF4S3JRV1VfaFhtc1RST01UUC1tRmpUYTFJUDV3N1BRN25ENFdxcGdjMW5hZWlnTnI0UDdMWDR4S2xDbTZPY0VGeHF6TDU?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Inc (EBS) Stock Price Today: $7.50", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE8zdXEtQkVuSWlxajJHLXp1TXRIcllfUTMtRVo3Ul83Ri1IYmhJYm1kVWw5b0ZmakpKSC1xeURoTTdNbTZaOGlCSmJwTFNoc0pqbHBwUGdn?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T06:35:18+00:00", "published_display": "02 Feb 2026 06:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQT3NjSEVzWDFWUGM5YnBpRkcyenJUUzgyd1c5QkxyalRpX3NMVDZEN3VCdTdhUUNsYWwyRzA1Y1R5SHFOY3drVnRBQzhYdk90WjdLNFh0X3VrMTdqbmJINzlhM1JUdTlrOWhodnNTbFRsSWtEWC12UTV0TGxyd0JHY0Vjcl9CNGhPR0ZQZ3RmRkdmNjVtMFlDQjY2RHk0TUphQW5UYVIxZk9lQUZYbWUtV3M4MldpelJFTlYtUEpFdzd6cDd4REp0RUJDYkd1UG0xLWs3aThUMFVTZ3hXTWs2dWFTWG5lR1U?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-15T22:09:08+00:00", "published_display": "15 Jan 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-20T08:00:00+00:00", "published_display": "20 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions (EBS): Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-02T07:00:00+00:00", "published_display": "02 Nov 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is \u2018Significantly Undervalued\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOWThJUHFGUjM4WFNPS0NrVjJKOFk5MmRTTnV6UHJvSVRrTnRYS0hOYk5keFNfbUplazIxWUU0bkNSbnRXU294Vmx0X2tHRHNvd1oxNzE5aXlzdHpQZW5tbU5xbHZVNmV0Z1o4blJFeG9fakdPOHFLd3ZkeXprZ1NMOF9CZ1Z2dVJDYlBuWFlqWjlPYV9FeWp4dFZTUXJWNVV4S3pUclZ6MFN4OUpjUmVHdU1qeEl3MVY1N3ltMEhhbkdOMmhITDk1WllOQmhlRVJOR1NIaHpEdm1BS0N2QTF4eUladw?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-19T16:16:57+00:00", "published_display": "19 Sep 2025 16:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sellers Might Regret Selling Emergent BioSolutions Shares at a Lower Price Than Current Market Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 91, "total_relevant": 54, "sentiment_summary": {"positive": 7, "negative": 10, "neutral": 37, "score": 50, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 7, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 8.05, "latest_week": "2026-07-10", "one_week_move": -2.8, "four_week_move": -3.2, "twelve_week_move": -8.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.318764, "market_dynamics_buy_signal": false, "relative_strength": -22.431618, "fair_value_gap": 14.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 45.0, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.8% over one week, -3.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Market source", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "MT Newswires", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 8}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.8% over one week, -3.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Emergent BioSolutions (EBS) AGM 2026 Summary"}], "updated_at": "2026-07-18T02:27:28.755442+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}